2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Clinical Procedures, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Women’s Health, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, CHIP, Genomics, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Bone Marrow Failure Syndromes, Aplastic Anemia, Genetic Disorders, Immunology, Autoimmune Disorders, Autoimmune Hemolytic Anemia, GVHD, Infectious Diseases, Viral, Bacterial, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, CLL, LGL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Research, AML, Translational Research, MDS, MPN, CML, Clinical Research, Epidemiology, Health Outcomes Research, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Pediatric
PAPER

2505 Clinical implications of recipient clonal hematopoiesis in allogeneic hematopoietic cell transplantation: Clonal dynamics and beyond

Jessica El-Asmar, MD, MPH, Joy Nakitandwe, PhD, MSc, BSc2, Abhinav Anand Vayal Veettil3, Hong Li, PhD4, Arda Durmaz, PhD5, Moaath Mustafa Ali, MD, MPH6, Akriti G Jain, MD, FACP7, John Carlos Molina, MD, MEd8, Sophia Rebecca Balderman, MD9, Aaron T. Gerds, MD, MS10, Sudipto Mukherjee, MD, PhD, MPH11, Anjali Sunder Advani, MD12, Hetty Carraway, MD, MBA13, Betty Hamilton, MD14, Claudio Brunstein, MD, PhD15, Matt Kalaycio, MD16, Marcelo Pasquini, MD17, Ronald Sobecks, Professor of Medicine18, Andrew Trunk, MD19, Abhay Singh, MD, MPH20
1 Cleveland Clinic Foundation, Cleveland, Ohio, United States
2 Cleveland Clinic Foundation, Cleveland, Ohio, United States
3 Cleveland Clinic Foundation, Cleveland, Ohio, United States
4 Cleveland Clinic Foundation, Cleveland, Ohio, United States
5 Cleveland Clinic Foundation, Cleveland, Ohio, United States
6 Cleveland Clinic Foundation, Cleveland, Ohio, United States
7 Cleveland Clinic Foundation, Cleveland, Ohio, United States
8 Cleveland Clinic Foundation, Cleveland, Ohio, United States
9 Cleveland Clinic Foundation, Cleveland, Ohio, United States
10 Cleveland Clinic Foundation, Cleveland, Ohio, United States
11 Cleveland Clinic Foundation, Cleveland, Ohio, United States
12 Cleveland Clinic Foundation, Cleveland, Ohio, United States
13 Cleveland Clinic Foundation, Cleveland, Ohio, United States
14 Cleveland Clinic Foundation, Cleveland, Ohio, United States
15 Cleveland Clinic Foundation, Cleveland, Ohio, United States
16 Cleveland Clinic Foundation, Cleveland, Ohio, United States
17 Cleveland Clinic Foundation, Cleveland, Ohio, United States
18 Cleveland Clinic Foundation, Cleveland, Ohio, United States
19 Cleveland Clinic Foundation, Cleveland, Ohio, United States
20 Cleveland Clinic Foundation, Cleveland, Ohio, United States

Background: The stress of allogeneic hematopoietic cell transplantation (allo-HCT) can exert selective pressures to drive pathogenic clonal hematopoietic (CH) evolution, thereby shaping post-HCT molecular dynamics. Because CH is common in myeloid neoplasms yet difficult to distinguish from residual leukemia-associated variants, in our current analysis alterations not classified as established leukemia drivers were conservatively termed non-driver mutations (NDMs). We analyzed the characteristics of NDMs alongside patient-related factors, disease risk classification, conditioning regimens, and other transplant-related variables. We particularly aimed to identify low-level clones before and after allo-HCT that may otherwise go undetected but could influence post-HCT outcomes.

 

Methods: We conducted a single-institution retrospective cohort study to analyze clonal dynamics in adult patients with myeloid malignancies who received allo-HCT between 2019 and 2023. Our main objective was to identify the persistence of low-level mutations [variant allele frequency (VAF) <5%] and their association with relapse risk and other patient outcomes post allo-HCT, in comparison to those with undetectable mutations and those with mutations at higher VAFs. The main genes of interest were: ASXL1, CEBPA, CHEK2, DNMT3A, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, PPM1D, SF3B1, SRSF2, TET2, TP53, U2AF1, ZRSR2. The presence of NLDMs was determined based on Next-Generation Sequencing at time of diagnosis pre-HCT and at day 100 post-HCT (as well as at relapse if applicable). The association between clonal dynamics with relapses or incidence of clinically significant acute and chronic GVHD post allo-HCT was evaluated using Gray’s test and Cox hazard model with competing risk, while the impact on progression-free survival (PFS) and overall survival (OS) was examined using Kaplan-Meier method. Multivariate analysis included age, performance status, HCT-CI, and disease risk index (DRI).

 

Results: At our institution, 346 adult patients received allo-HCT for AML (54%), MDS (27%), MPN (10%), CMML (5%), or AA (4%) between 2019 and 2023, of which only 92 patients had paired pre-HCT at diagnosis and post-HCT molecular data. Patients predominantly received reduced intensity/nonmyeloablative conditioning (67%) and PTCy-based GVHD prophylaxis (68%). DRI was the strongest predictor of relapse: high DRI (23% of patients) had an adjusted hazard ratio (aHR) of 5.29 compared to low DRI (10% of patients). Forty-one percent of patients had intermediate or adverse cytogenetics pre-transplant, with 65% either remaining the same or worsening after transplant – this subgroup was found to have the highest cumulative incidence of relapse at 36 months with 2-fold increased risk (aHR 2.08, 95% 1.08-4.00). In our cohort, cytogenetic changes (whether more metaphases or acquiring abnormalities) had no significant impact on GVHD cumulative incidence, PFS (log-rank P=0.88), or OS (log-rank P=0.75).

Among 92 patients with paired molecular testing, allo-HCT was associated with substantial reduction in detectable mutational burden, with 2-12% of pre-HCT positive-gene patient observations becoming undetectable. Clearance was highest for IDH1 (87.5%), SRSF2 (85.7%), NPM1 (75.0%), and FLT3 (71.4%). In contrast, TP53 persisted in 66.7% of patients, and SF3B1 in 71.4% of patients, identifying potentially resistant molecular subsets after allo-HCT. ASXL1 showed marked clonal turnover: 11/19 baseline mutations cleared, 8/19 persisted, and 6 newly emerged post-HCT. Despite this pronounced molecular turnover, no significant associations with relapses, PFS, or OS were detected.

 

Conclusion: In our cohort, allo-HCT effectively reduced molecular burden across leukemia- and non-leukemia driver-associated mutations, particularly IDH1, NPM1, FLT3, SRSF2, JAK2, DNMT3A, and TET2; however, TP53 and SF3B1 frequently persisted, while ASXL1 and NRAS demonstrated bidirectional clonal turnover.  Although molecular dynamics were not statistically associated with clinical outcomes, this may be limited by sparse paired testing and few gene-specific events, rather than an absence of biologically meaningful effects. Our study shows the importance of serial molecular assessments post-HCT to define the prognostic significance of clonal dynamics and guide gene-specific allo-HCT strategies.

Jessica El-Asmar, MD, MPH: No relevant conflicts of interest to declare.